Shares of Jubilant Life Sciences gained 4 per cent today as the company has received approval from the US health regulator to market generic levofloxacin tablets, used to treat various infections including pneumonia.
The stock ended the day with a gain of 3.99 per cent at Rs 177.35 on the BSE. In intra-day, it surged 5.45 per cent to Rs 179.85.
At the NSE, shares of Jubilant Life climbed 3.66 per cent to close at Rs 176.75.
Following the gain in the stock, the company's market valuation rose by Rs 108.85 crore to Rs 2,824.85 crore.
The company has received approval from the US Food and Drug Administration (USFDA) to market generic version of Levaquin tablets in strengths of 250 mg and 500 mg in the American market, the firm said in a statement.
The drug is used to treat adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
